ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals, revising the target price to Rs 1,300. The brokerage anticipates revenue, EBITDA, and PAT to grow at a CAGR of 10.3%, 15.0%, and 20.8% respectively, between FY25-27E. Slower growth in India prompts a slight reduction in revenue and EBITDA estimates for FY26/27E.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets